Armistice Capital’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Armistice Capital’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$565	Hold	50,000	–	–	﹤0.01%	260
2025 Q4	$705	Hold	50,000	–	–	﹤0.01%	363
2025 Q3	$845	Hold	50,000	–	–	﹤0.01%	327
2025 Q2	$1.08K	Hold	50,000	–	–	﹤0.01%	202
2025 Q1	$910	Hold	50,000	–	–	﹤0.01%	222
2024 Q4	$1.73K	Hold	50,000	–	–	﹤0.01%	217
2024 Q3	$1.75K	Hold	50,000	–	–	﹤0.01%	253
2024 Q2	$995	Hold	50,000	–	–	﹤0.01%	250
2024 Q1	$615	Sell	50,000 -950,000	-95%	-$13.1K	﹤0.01%	331
2023 Q4	$18K	Hold	1,000,000	–	–	﹤0.01%	273
2023 Q3	$6.2K	Hold	1,000,000	–	–	﹤0.01%	248
2023 Q2	$15.8K	Sell	1,000,000 -1	-0%	–	﹤0.01%	213
2023 Q1	$40K	Buy	1,000,001 +1	+0%	–	﹤0.01%	213
2022 Q4	$30K	Hold	1,000,000	–	–	﹤0.01%	180
2022 Q3	$148K	Hold	1,000,000	–	–	﹤0.01%	169
2022 Q2	$65	Hold	1,000,000	–	–	﹤0.01%	170
2022 Q1	$170K	Hold	1,000,000	–	–	﹤0.01%	132
2021 Q4	$370K	Hold	1,000,000	–	–	0.01%	135
2021 Q3	$800K	Buy	+1,000,000	New	+$780K	0.01%	124

Other funds holding KTTAW

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Armistice Capital's KTTAW Position: Q1 2026 in Review

Armistice Capital held its Pasithea Therapeutics Warrants (KTTAW) position steady in Q1 2026 at 50,000 shares worth $565. The position accounts for ﹤0.01% of the portfolio, ranked #260.

Armistice Capital first reported a position in KTTAW in Q3 2021 and has held it in 19 quarters since. The position peaked at $800K in Q3 2021. 5 funds tracked by Wall St. Rank hold KTTAW as of Q1 2026.

Armistice Capital held 50,000 shares of Pasithea Therapeutics Warrants worth $565 as of Q1 2026.
Armistice Capital left its Pasithea Therapeutics Warrants share count unchanged in Q1 2026.
Pasithea Therapeutics Warrants made up ﹤0.01% of Armistice Capital's portfolio in Q1 2026, its #260 holding.
Armistice Capital first reported a position in Pasithea Therapeutics Warrants in Q3 2021 and has held it in 19 quarters since.
Armistice Capital's Pasithea Therapeutics Warrants position peaked at $800K in Q3 2021.
5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.